Adolor Corp

Adolor — Technical Presentation (January 2004)

22 slides from Adolor's technical presentation, Jan 14, 2004

  1. Slide 1: Results from Entereg Phase 3 Clinical Study 14CL308

    adolor CORPORATION Results from Entereg™ Phase 3 Clinical Study 14CL308 January 13, 2004

  2. Slide 2: Forward-Looking Statements

    Alin, Forward-Looking Statements adiiior This oral presentation and the questions and answers that follow contain forward- looking statements including but not limited to the following: * Our plans to submit Entereg™ clinical studies 302, 306, 308 and 313 in an NDA. + Our NDA submission target date

  3. Slide 3: POI Phase 3 Program Summary

    ™ Entereg™ for the Management of adolor Postoperative Ileus Conronation POI Phase 3 Program Summary Primary iy Study (Enrolled) | gee ttive Population (% MITT) (N= 2,146) a7 Large Bowel Resection (70%) enast) Efficacy Radical Hysterectomy (7%) Simple Hysterectomy (23%) 313 , Bowel Resection (96%) Ef

  4. Slide 4: Study Design

    Entereg™ for the Management of ndillo? Postoperative Ileus -- Study 14CL308 conmgyrew Study Design * Double-blind, placebo-controlled, randomized, multi-center + Male or Female 18 years or older * 666 subjects enrolled across 3 treatment groups (Entereg™ 6 or 12 mg, or placebo) * Large or Small Bowe

  5. Slide 5: Study Design

    Entereg™ for the Management of a Postoperative Ileus -- Study 14CL308 conmgyrew Study Design ¢ Subjects were to receive their first dose at least two hours prior to surgery, and then twice a day until Hospital Discharge or up to 7 days post-surgery * Subjects were scheduled for postoperative pain ma

  6. Slide 6: Primary and Secondary Efficacy Endpoints

    Entereg™ for the Management of ndillo? Postoperative Ileus -- Study 14CL308 conmgyrew + Primary Efficacy Endpoint = Time to recovery of gastrointestinal (G.1.) function (composite endpoint is upper AND lower G.I. recovery) = Time to upper G.I. Recovery: tolerating solid foods = Time to lower G.I. Re

  7. Slide 7: Subjects Enrolled

    Entereg™ for the Management of Postoperative Ileus -- Study 14CL308 Subjects Enrolled (N = 666) Modified Intent-to-Treat (N= 615) Placebo Entereg 6 mg (N=207) (N= 204) Entereg 12 mg (N=204) Completed = 84.1% Completed = 89.2% DIC = 10.8% AE=16 Other =6 January 13, 2004 ?

  8. Slide 8: Overall Demographics – MITT Population

    Entereg™ for the Management of ae Postoperative Ileus -- Study 14CL308 conmgyrew Overall Demographics — MITT Population Placebo 6mg 12mg Overall (N=207) (N=204) (N=204) (N=615) Mean Age 56 56 58 57 Female (%) 65.7 61.8 64.2 63.9 Caucasian (%) 74.9 74.5 78.9 76.1 January 13, 2004 ’

  9. Slide 9: Time to Recovery of GI Function – Primary Endpoint

    Entereg™ for the Management of ndillo? Postoperative Ileus -- Study 14CL308 conmgyrew Time to Recovery of GI Function — Primary Endpoint 6 mg dose vs. placebo ° Hazard ratio = 1.20 (P= 0.079) + Approximately 8 hours earlier average time to recovery of GI function 12 mg dose vs. placebo ° Hazard rati

  10. Slide 10: Time to Hospital Discharge Order Written

    Entereg™ for the Management of ndillo? Postoperative Ileus -- Study 14CL308 conmgyrew Time to Hospital Discharge Order Written 6 mg dose vs. placebo ¢ Hazard ratio = 1.31 (P< 0.01) * Approximately 14 hours earlier average time to hospital discharge order written 12 mg dose vs. placebo ° Hazard ratio

  11. Slide 11: Hospital Discharge Order Written by Postoperative Day

    Entereg™ for the Management of adilo> Postoperative Ileus -- Study 14CL308 contimarso™ Additional Analysis: Hospital Discharge Order Written by Postoperative Day % of Subjects 30 25 Est. Avg. 20 Days 15 Placebo 5.4 Bi2mg 48 10 + s4 o4 109203 4 5 6 7 8 9 10 11+ Post Operation Days January 13, 2004

  12. Slide 12: Study Endpoints

    Entereg™ for the Management of Vg oN adolor Postoperative Ileus -- Study 14CL308 —" Study Endpoints MITT Population (12 mg dose) _| Time to: HR P-Value_ ]]Mean Diff (Hrs)! Discharge Order 1.28 <0.05 15.2 Ready for Discharge 1.29 <0.05 118 First BM 1.49 <0.01 16.1 First Solids 1.19 NS 77 First Flatus

  13. Slide 13: Safety and Adverse Events

    Entereg™ for the Management of Adillo: Postoperative Ileus -- Study 14CL308 contearien + Entereg™ was generally well tolerated * Most frequent adverse events were : Safety Population Placebo omg i2mg (N=224) (N=220) (N=221) ‘Nausea 54.0% 47.7% 50.2% Vomiting 25.0% 20.0% 20.8% Pruritus 14.3% 10.5% 12

  14. Slide 14: Time to Recovery of GI Function – Primary Endpoint

    Entereg™ for the Management of Postoperative Ileus Time to Recovery of GI Function — Primary Endpoint shady ae ma te 14CL302 <0.01 0.059 14CL313 <0.05 <0.01 14CL308 0.079 0.038 January 13, 2004 q

  15. Slide 15: Time to Discharge Order Written – Secondary Endpoint

    T™ fr Entereg for the Management of a? Postoperative Ileus Conromarion Time to Discharge Order Written — Secondary Endpoint 6 mg 12 mg Study . . Mean Diff (hrs)! | Mean Diff (hrs)! 14CL302 14.1 75 14CL313 13.4 19.5 14CL308 14.3 15.2 As compared to placebo January 13, 2004

  16. Slide 16: Bowel Resection Patients

    Alin, Entereg™ for the Management of Ad@lor Postoperative Ileus a" Bowel Resection Patients LSOM (12mg dose) __ 308 Bowel Resection Subgroup 313 MITT Time to: HR | P-Value | Mean Diff | HR | P-Value | Mean Diff (hours)! (hours)! Discharge Order 1356 | <0.01 213 142 | <0.01 19.5 Ready for D/C 142 [|

  17. Slide 17: Treatment Emergent AE - Nausea

    Entereg™ for the Management of Postoperative Ileus Treatment Emergent AE - Nausea Study Placebo 6 mg 12 mg 14CL302 67% 64% 57% 14CL313 64% 61% 55% 14CL308 54% 48% 50% January 13, 2004

  18. Slide 18: Treatment Emergent AE - Vomiting

    Entereg™ for the Management of Postoperative Ileus Treatment Emergent AE - Vomiting January 13, 2004 Study Placebo 6 mg 12 mg 14CL302 32% 25% 15% 14CL313 26% 24% 20% 14CL308 25% 20% 21%

  19. Slide 19: Subjects Re-hospitalized Post Discharge

    Entereg™ for the Management of adolor Postoperative Ileus Subjects Re-hospitalized Post Discharge (within 10-day Follow-up Period) Study Placebo 6mg 12mg 44CL302 8.5% 5.3% 2.7% 14CL308 6.7% 45% 4.5% | 14CL313 7.9% 41% 4.0% January 13, 2004

  20. Slide 20: NGT Insertion Post Surgery (MITT)

    Entereg™ for the Management of ae Postoperative Ileus Conronarion NGT Insertion Post Surgery (MITT) Study Placebo 6mg 12mg 14CL302 6.9% 7.2% 14CL313 14. 8% 4.8% 14CL308 8.2% 5.9% January 13, 2004

  21. Slide 21: Summary: Studies 14CL302, 14CL308, and 14CL313

    Entereg™ for the Management of a Postoperative Ileus -- Phase 3 Program commen Summary: Studies 14CL302, 14CL308, and 14CL313 * Compared to the placebo group: = Entereg™ achieved either a statistically significant difference or a positive trend in the primary endpoint, Time to GI Recovery, in all th

  22. Slide 22: Adolor Corporation

    ‘adolor CORPO

Adolor — Technical Presentation (January 2004) on 6ix